

## Press release

## Elos and Novo Nordisk have signed agreement on expanded cooperation and Elos has decided to open a facility in China

Since 1985, the Elos subsidiary, Elos Pinol, which is part of the Elos Group's medical technology operations, has been involved in the development and production of mechanical components for Novo Nordisk's various generations of multiple-use insulin pens. Novo Nordisk is a global leader in diabetes care. Deliveries have been made to Novo Nordisk's facility in Hilleröd, Denmark.

Elos and Novo Nordisk have now signed an agreement pertaining to expanded cooperation, including continued development and production cooperation in the manufacture of multipleuse insulin pens. The new agreement also encompasses deliveries to Novo Nordisk's facility in Tianjin, China. During 2010, the Elos Group will be establishing an operation in Tianjin for deliveries to Novo Nordisk and other customers in the medical technology area. The facility is expected to come on line during the third quarter of 2010. At the end of 2011, the operation will have approximately 80 employees.

"We view our cooperation with Novo Nordisk as a key strategic feature of the development of our medical technology operations," says Elos CEO, Göran Brorsson. "The expanded cooperation will now facilitate the establishment of a unit in Tianjin, China. This is an important strategic step towards achieving the Group's objective of establishing the company in the growing Asian market. The establishment shall initially be viewed at a basis for deliveries to the Group's medical technology customers that are now establishing themselves in the Chinese market."

Elos is one of Europe's leading system suppliers of such medical technology products and components as dental and orthopaedic implants and instruments. Through two units, Elos Medical in Timmersdala, Sweden, and Elos Pinol in Görlöse, Denmark, customers are offered an overall solution – from development and design to production and sterile packaging of the finished product. The operation has sales of nearly SEK 300 M and has about 240 employees.

Lidköping, November 18, 2009

Elos AB (publ)

For further information, please contact Göran Brorsson, CEO, +46 510 48 43 65 or +46 70 511 78 60.

Elos' operations comprise development, manufacturing and marketing to international customers who need complex products used in demanding environments in the Medical Technology and Precision Technology business areas. For additional information, visit www.elos.se.

The information contained in this press release is of the kind that Elos AB has to make public according to the Securities Market Act and/or the Financial Instruments Trading Act.

The information was made public on November 18, 2009 at 08.30 (CET).